Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Lunning, Matthew ^{[1
]}

Deger, Kristen A. ^{[2
]}

Liu, Fei Fei ^{[3
]}

Elsada, Ahmed ^{[3
]}

Klijn, Sven L. ^{[3
]}

Litkiewicz, Michal ^{[4
]}

Franco-Villalobos, Conrado ^{[5
]}

Sorensen, Sonja V. ^{[2
]}

机构：

[1] Univ Nebraska Med Ctr, Omaha, NE USA

[2] Evidera, Bethesda, MD USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] Evidera, London, England

[5] Evidera, Montreal, PQ, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CT; LBCL; large B-cell lymphoma; lisocabtagene maraleucel; axicabtagene ciloleucel; cost-effectiveness; CAR; chimeric antigen receptor T-cell therapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT-107

引用

页码：S517 / S517

页数：1